title: EULAR recommendations for the management of primary small and medium vessel vasculitis.
abstract: OBJECTIVE
  To develop European League Against Rheumatism (EULAR) recommendations for the management of small and medium vessel vasculitis.
  
  
  METHODS
  An expert group (consisting of 10 rheumatologists, 3 nephrologists, 2 immunologists, 2 internists representing 8 European countries and the USA, a clinical epidemiologist and a representative from a drug regulatory agency) identified 10 topics for a systematic literature search using a modified Delphi technique. In accordance with standardised EULAR operating procedures, recommendations were derived for the management of small and medium vessel vasculitis. In the absence of evidence, recommendations were formulated on the basis of a consensus opinion.
  
  
  RESULTS
  In all, 15 recommendations were made for the management of small and medium vessel vasculitis. The strength of recommendations was restricted by low quality of evidence and by EULAR standardised operating procedures.
  
  
  CONCLUSIONS
  On the basis of evidence and expert consensus, recommendations have been made for the evaluation, investigation, treatment and monitoring of patients with small and medium vessel vasculitis for use in everyday clinical practice.
authors.affiliation: University of Oxford, Oxford, UK.
authors.forename: C
authors.initials: C
authors.lastname: Mukhtyar
authors.forename: L
authors.initials: L
authors.lastname: Guillevin
authors.forename: M C
authors.initials: MC
authors.lastname: Cid
authors.forename: B
authors.initials: B
authors.lastname: Dasgupta
authors.forename: K
authors.initials: K
authors.lastname: de Groot
authors.forename: W
authors.initials: W
authors.lastname: Gross
authors.forename: T
authors.initials: T
authors.lastname: Hauser
authors.forename: B
authors.initials: B
authors.lastname: Hellmich
authors.forename: D
authors.initials: D
authors.lastname: Jayne
authors.forename: C G M
authors.initials: CG
authors.lastname: Kallenberg
authors.forename: P A
authors.initials: PA
authors.lastname: Merkel
authors.forename: H
authors.initials: H
authors.lastname: Raspe
authors.forename: C
authors.initials: C
authors.lastname: Salvarani
authors.forename: D G I
authors.initials: DG
authors.lastname: Scott
authors.forename: C
authors.initials: C
authors.lastname: Stegeman
authors.forename: R
authors.initials: R
authors.lastname: Watts
authors.forename: K
authors.initials: K
authors.lastname: Westman
authors.forename: J
authors.initials: J
authors.lastname: Witter
authors.forename: H
authors.initials: H
authors.lastname: Yazici
authors.forename: R
authors.initials: R
authors.lastname: Luqmani
mesh_terms: D019268:Antibodies, Antineutrophil Cytoplasmic / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D010951:Plasma Exchange; D014657:Vasculitis / Q000175:diagnosis / Q000628:therapy*
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D015415:Biomarkers; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D008727:Methotrexate